Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Olema Oncology (Nasdaq: OLMA) granted inducement stock options to two new employees to purchase an aggregate of 65,000 shares, effective December 1, 2025. The awards were approved by the Compensation Committee under the 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The options vest over four years (25% after one year, then monthly over three years), have a 10-year term, and an exercise price of $27.95 per share, equal to the last reported Nasdaq sale price on December 1, 2025. The grants are subject to the Inducement Plan terms.

SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 65,000 shares of the Company's common stock, effective as of December 1, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $27.95 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on December 1, 2025. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.

Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

What did Olema Oncology (OLMA) announce on December 2, 2025 about stock option grants?

Olema announced inducement stock options to two new hires for an aggregate of 65,000 shares, effective Dec 1, 2025.

What is the exercise price and term for the OLMA inducement options granted Dec 1, 2025?

The options carry an exercise price of $27.95 per share and a 10-year term.

How do the Olema (OLMA) inducement stock options vest?

They vest over 4 years: 25% after one year, then the remainder in 36 equal monthly installments, subject to continued employment.

Under what plan were the OLMA inducement awards granted and which Nasdaq rule applies?

Awards were granted under the 2022 Inducement Plan and reported under Nasdaq Listing Rule 5635(c)(4).

Will the OLMA inducement grants immediately dilute existing shareholders?

The announcement states the number of options (65,000) but does not quantify immediate dilution or outstanding share count.

Who approved the Olema inducement option grants for OLMA on Dec 1, 2025?

The grants were approved by the Compensation Committee of Olema’s Board of Directors.